The effects of somatostatin and of the three octapeptide SS-analogs that are available for clinical use (octreotide, BIM-23014 and RC-160) on hormone release by primary cultures of 15 clinically nonfunctioning pituitary adenomas (NFA), 7 prolactinomas, and 2 insulinomas were investigated. In the pituitary adenoma cultures, a comparison was made with the effects of the dopamine (DA) agonists bromocriptine and/or quinagolide. In 5 NFAs, 2 prolactinomas and 1 insulinoma somatostatin receptor (subtype) expression was determined by ligand binding studies and by in situ hybridization to detect sst 1 , sst 2 , and sst 3 messenger RNAs (mRNAs).
In the 2 other cultures, both compounds were equally effective. In 2 insulinoma cultures, insulin release was inhibited by SS, and by octapeptide SS-analogs in only one. The presence or absence of an inhibitory effect by octreotide was in all cases in parallel with the presence or absence of the inhibitory effect by BIM-23014 and RC-160.
Autoradiographic studies using [ 1 and/or sst 3 mRNA expression, whereas no sst 2 expression was found.
In conclusion, a dissociation between the inhibitory effects of SS on the one hand and of the octapeptide SS-analogs octreotide, BIM-23014 and RC-160 on the other hand, is observed in a small subgroup of NFAs, prolactinomas, and insulinomas, suggesting that novel sst subtype specific SS-analogs might be of benefit in the treatment of selected patients with somatostatin receptor positive secreting tumors not responding to octapeptide SS-analogs. However, in the majority of NFAs and prolactinomas, DA-agonists were equally or more effective than SS in the suppression of tumoral secretion products. (J Clin Endocrinol Metab 82: 3011-3018, 1997) R ECENTLY, five distinct somatostatin receptor (sst) subtypes have been cloned and characterized (1) (2) (3) (4) . All sst subtypes bind native somatostatin (SS) with high affinity, whereas differences have been found between sst [1] [2] [3] [4] [5] in the binding of structural analogs of SS. Octreotide, which is the most widely used SS-analog, successfully controls hormonal hypersecretion in a majority of patients with neuroendocrine tumors (5) . This SS-analog binds with a high and relative high affinity to sst 2 and sst 5 , respectively, with low affinity to sst 3 , and has no affinity to sst 1 and sst 4 . Two other SSanalogs, BIM-23014 (lanreotide) and RC-160 (vapreotide), show a binding profile comparable to that of octreotide (1) (2) (3) (4) .
From several studies using different techniques, it has become clear now that the majority of the human sst positive tumors express multiple sst subtypes. While the majority of the neuroendocrine tumors carry sst with a high affinity for native SS as well as for the octapeptide SS-analog octreotide, small subgroups of tumors have been described with high affinity binding sites for SS but not for octreotide (6) . Among these tumors are certain insulinomas, carcinoids, medullary thyroid carcinomas, ovarian tumors, and pituitary adenomas. Absence of the sst 2 subtype has been associated with an absent hormonal response to treatment with octreotide, suggesting that sst 2 is involved in the antihormonal actions of SS-analogs like octreotide (7, 8) , whereas sst 2 seems to be involved in the inhibition of GH secretion in rats (9) . So far, however, the functional role of the other sst subtypes, is unclear.
In a previous study, we have compared the effects of the three SS-analogs (octreotide, BIM-23014, and RC-160) on hormone release by pituitary GH-adenomas and a gastrinoma in vitro (10) . In this study, we found that GH-adenomas with an absent hormonal response to octreotide were unresponsive to BIM-23014 and RC-160 as well. Still, two major questions remain. First, are there differences between the inhibitory effects of the above mentioned three clinically applicable SS-analogs in other types of secreting tumors? Second, is there evidence for a functional role of sst subtypes other than those with a high affinity for octapeptide SS-analogs?
In order to further investigate these questions, we have compared in the present study the effects octreotide, BIM-23014, and RC-160 with that of native SS on hormone release by the cultured cells prepared from 15 NFAs, 7 prolactinomas, and 2 insulinomas. In the pituitary adenoma cultures, a comparison with the effects of dopamine agonists was also made. Whereas several authors have described the effects of either SS or octreotide on NFAs (11, 12) , a direct comparison between SS and SS-analogs on hormone release by NFAs has not been made yet.
Materials and Methods Patients
Pituitary tumor samples were obtained by transsphenoidal operation from 18 patients with NFAs and from 7 patients with prolactinomas, as described previously (13) . Tumor samples of 2 insulinomas were obtained within 30 min after surgical removal of the tumors. Diagnosis was made on the basis of clinical and biochemical characteristics of the patients, in combination with (immuno)histochemistry of the tumor samples. All patients gave their informed consent for the use of tumor material for research purposes. When sufficient adenoma tissue was obtained, pieces were frozen on dry ice and stored at Ϫ80 C.
Cell dispersion and cell culture.
Fifteen out of 18 NFAs and 7 prolactinomas were used for the cell culture studies. Single cell suspensions of the pituitary adenoma tissues were prepared by enzymatic dissociation with dispase as described in detail previously (13) . Tumor tissue from the insulinoma patients was dissociated as described (14) .
Short-term incubation of monolayer cultures. the dissociated cells were plated in 48-well plates (Costar, Cambridge, MA) at a density of 10 5 (prolactinomas and insulinomas) or 2 ϫ 10 5 (NFAs) cells per well per 1 ml culture medium. After 3-4 days, the medium was changed, and 72-h incubations without or with SS, SS-analogs, or DA-agonists were started. At the end of the incubation, the medium was removed and centrifuged for 5 min at 600 ϫ g. The supernatant was collected and stored at Ϫ20 C until analysis. (15) . The isolated tumor cells were plated in Transwell-COL membranes (Costar, Badhoevedorp, The Netherlands) at a density of 10 5 (prolactinomas and insulinomas) or 2 ϫ 10 5 (NFAs) cells per well. The transwells were then placed into multiwell plates (24-well, Costar) containing 1 ml culture medium. After 24 h, the transwells were transferred to wells containing fresh medium (without or with test substances). Every 3-4 days, the cells were placed into fresh medium and the incubation media were collected and stored at Ϫ20 C until determination of hormone concentrations.
Long-term incubation studies in Transwells
In all experiments SS (SS-14 and/or SS-28), octapeptide SS-analogs (octreotide, BIM-23014, RC-160) and DA-agonists (bromocriptine and/or quinagolide) were used at a concentration of 10 nm. The cells were cultured at 37 C in a CO 2 -incubator. The culture medium consisted of MEM D-valine with Earle's salts supplemented with nonessential amino acids, sodium pyruvate (1 mmol/L), 10% FCS, penicillin (1 ϫ 10 5 U/L), fungizone (0.5 mg/L), l-glutamine (2 mmol/L), and sodium bicarbonate (2.2 g/L). Unfortunately, generally not enough tumor material was obtained to test each tumor on its responsiveness to all of the above indicated drugs.
Hormone determinations
Human PRL, LH, and FSH concentrations in the media were determined by immunoradiometric assays (MedGenix Diagnostics, Fleurus, Belgium) as described previously (13, 15) . Glycoprotein ␣-subunit concentrations were determined by an immunoradiometric assay from Immunotech S. A. (Marseille, France). Insulin concentrations were determined by a double antibody RIA as described (14) . Dilution of PRL, LH, FSH, ␣-subunit and insulin in the media was in parallel to the respective standards supplied with the kits.
Test substances
Somatostatin-14 (SS-14) was obtained from Sigma (St. Louis, MO). BIM-23014 (lanreotide) and somatostatin-28 (SS-28) were obtained from Bachem (Hannover, Germany). RC-160 (vapreotide) was obtained from Peninsula (Belmont, CA). Octreotide, bromocriptine and quinagolide (CV205-502) were obtained from Sandoz Pharma (Basle, Switzerland).
Receptor autoradiography
Receptor autoradiography was carried out as described by Reubi et al., (16) . Ten-micrometer sections were mounted onto precleaned gelatin coated microscope slides, and stored at Ϫ80 C. Adjacent sections were used for in situ hybridization and processed further as described below. To wash out endogenous somatostatin, the sections were preincubated at room temperature for 10 minutes in 170 mm Tris-HCl, pH 7.4. Thereafter, the sections were incubated for 60 minutes at room temperature in 170 mm Tris-HCl, pH 7. The incubated sections were washed twice for 5 min in incubation buffer containing 0.25% BSA and once in incubation buffer without BSA. After a short wash with distilled water to remove salt, the sections were air dried and exposed to Kodak X-OMAT AR or Hyperfilm-3 H (Amersham) for 3-7 days in x-ray cassettes. Histology was performed on hematoxylin-azophloxine stained sequential cryosections.
In situ hybridization histochemistry of sst 1 , sst 2 , and sst 3 mRNA
The protocol and oligonucleotides used for in situ hybridization were the same as described by Reubi et al. (17) . Forty-eight base pair oligonucleotides complementary to the bases coding for amino acids 2-17 of the hsst 1 mRNA sequence, 237-252 of the hsst 2 sequence, and 366 -381 of the hsst 3 sequence (17) were synthesized and purified over a Pharmacia NAP-10 column by Pharmacia Biotech (Roosendaal, The Netherlands). 3Ј-end labeling by using [␣-32 P]dATP (3000 Ci/mmol; Du Pont NEN , Boston, MA) was performed as described previously (18) . Specificity of hybridization signal obtained with the above oligonucleotide probes was established previously (17) . In our study, sequential cryostat sections of the tumors (see above) were incubated in duplicate with 32 P-labeled oligonucleotide probes without or with a 20-fold excess of unlabeled oligonucleotide to demonstrate specificity of the hybridization signal obtained. A tumor was considered positive for the respective mRNA when the hybridization signal obtained in a control section was displaced by a 20-fold excess of unlabeled oligonucleotide by more than 50%. The hybridization signals obtained were analyzed densitometrically.
Statistical analysis of the data
All data on hormone release are expressed in mean Ϯ se, n ϭ 4 wells per treatment group. All data were analyzed by ANOVA to determine overall differences between treatment groups. When significant differences were found by ANOVA, a comparison between treatment groups was made using the Newman-Keuls test. Table 1 shows basal release of ␣-subunit, FSH, and LH by cultured cells of NFAs 1-6. Five out of 6 NFA cultures secreted detectable amounts of ␣-subunit in vitro, 5 out of 6 secreted FSH, whereas only 2 of 6 (no. 1 and 2) secreted LH. Hormone release was not inhibited by SS-28 (10 nm), oct-reotide (10 nm), RC-160 (10 nm), or BIM-23014 (10 nm) in a 72-h exposure of the cells in 3 out of 6 cultures (nos. 2, 4, and 5, data not shown). In culture no. 5, however, the DA-agonist quinagolide (10 nm) significantly inhibited ␣-subunit and FSH release by 48 and 30%, respectively (P Ͻ 0.01 vs. control cells, data not shown). The effect of SS-28, SS-analogs, and quinagolide (all used at a concentration of 10 nm) on ␣-subunit or FSH release by NFA cultures 1, 3, and 6 is shown in Fig. 1 . Quinagolide significantly inhibited ␣-subunit or FSH release during a 72-h exposure in all cultures (P Ͻ 0.01 vs. control cells), whereas in cultures no. 1 and 3 both SS-28 and octreotide significantly inhibited hormone release (P Ͻ 0.01 vs. control cells). In culture no. 3, SS-28, octreotide, RC-160, and BIM-23014 were equally effective. However, in culture no. 6, which was sensitive to the inhibitory effect of SS-28, none of the three octapeptide SS-analogs were effective in inhibiting FSH release. In NFA culture no. 1, the response of FSH and LH release was comparable with that of ␣-subunit release, whereas in culture no. 3, ␣-subunit release was not inhibited (data not shown).
Results

Clinically nonfunctioning pituitary adenomas
In nine NFA cultures (nos. 7-15), the effects of bromocriptine (10 nm), SS-28 (10 nm), and the three SS-analogs (10 nm) were investigated during prolonged exposure in Transwell tissue culture inserts (15) . Four of these cultures (nos. 12-15) did not secrete detectable amounts of LH, FSH, or ␣-subunit (data not shown). Figure 2 shows the effects of the abovementioned drugs on ␣-subunit release by cultured cells from NFA no. 7 and no. 10. In the cells of patient 7, ␣-subunit release was progressively inhibited to the same extent by SS-28 and the three SS-analogs. The degree of inhibition after 2 weeks of exposure in vitro was comparable to that of bromocriptine. In NFA culture, no. 10 bromocriptine and SS-28 also increasingly inhibited ␣-subunit release, although bromocriptine was most effective. After drug withdrawal on day 14, these inhibitory effects recovered, suggesting that the increasing inhibitory actions of bromocriptine, SS-28 and SS-analogs, represented inhibition of hormone release and or production and not inhibition of cell proliferation. Table 2 shows the effects of bromocriptine, SS-28, and SS-analogs on ␣-subunit-, FSH and/or LH release by NFAs no. 7-11, at day 14 of incubation. In all NFA cultures (7-11) bromocriptine (10 nm) significantly inhibited hormone release. SS-28 significantly inhibited hormone release in cultures 7, 9, 10, and 11.
Octreotide, BIM-23014, and RC-160 significantly inhibited hormone release in culture no. 7.
Overall, hormone release was sensitive to DA-agonists in 9 out of 11, to SS-28 in 7 out of 11, and to SS-analogs in 3 out of 10 cultures. In three cases (nos. 6, 9, and 11) hormone release was sensitive to SS, but not to SS-analogs. In all cultures, except for one (no. 7), bromocriptine was the most effective compound.
Prolactinomas
Quinagolide (10 nm) significantly inhibited PRL release during a 72-h incubation in three prolactinoma cultures (nos. 1, 2, and 3) by 25, 33, and 50% respectively (data not shown). In these three cultures, octreotide (10 nm) did not significantly inhibit PRL release. At the same time, 10 nm RC-160 (in culture nos. 2 and 3) or 10 nm BIM-23014 (in culture no. 3) were also ineffective (data not shown).
In 4 prolactinoma cultures (nos. 4 -7), the effects of SS-28, octreotide, RC-160, BIM-23014, and bromocriptine (all at a concentration of 10 nm) were studied during prolonged incubation of the cells in Transwells. Figure 3 shows that PRL release by the cells of adenoma no. 4 was slightly sensitive to octreotide (statistically significant inhibition of PRL release at days 3, 10, and 14) but responded very well to SS-28 and bromocriptine (90 and 84% inhibition, respectively, day 14 of culture). In addition, we found that PRL release by the cells of patient 5 was also increasingly inhibited by bromocriptine and SS-28 (by 40 and 40%, respectively, day 14 of culture; P Ͻ 0.01 vs. control cells), in contrast to the slight (approximately 17%, day 14 of culture), but significant inhibition by the three SS analogs. Comparable to the NFA cultures, drug withdrawal on day 14 in culture no. 5, led to a recovery of PRL release. It is also important to note that the maximal inhibition of PRL release by both SS-28 and bromocriptine was considerably less in the culture of adenoma no. 5 in comparison with culture no. 4. Patient no. 5 had become insensitive to DA-agonist therapy, whereas patient no. 4 was operated because of intolerance to DA-agonist therapy. Table 3 shows the effects of the above compounds on PRL release by culture nos. 6 and 7, at day 14 of incubation. PRL release by adenoma cells from patients no. 6 and 7 (operated because of intolerance to DA-agonist therapy) was significantly inhibited by bromocriptine, and slightly by SS-28. Octreotide significantly inhibited PRL release in culture no. 6 only. The cells of patient 7 were unresponsive to octreotide, BIM-23014, and RC-160.
Overall, hormone release was sensitive to DA-agonists in all 7 prolactinoma cultures, to SS-28 4 of 4, and to octreotide in 3 of 7. In 2 cultures (nos. 4 and 5) hormone release was significantly inhibited by SS-28 and only slightly by octreotide, BIM-23014, and RC-160. In those cultures sensitive to both bromocriptine and SS-28, bromocriptine was the most potent compound in 2 out of 4 cultures (nos. 6 and 7). In the two other cultures, both compounds were equally effective. Table 4 shows the effect of SS-14, SS-28, and octreotide and RC-160 (72 h incubation) on insulin release by cultured cells of insulinoma no. 1. Both SS-14 (10 nm) and SS-28 (10 nm) 200,000 cells per well were plated in 24-well multiwell plates in 1 ml of MEM-Dval ϩ 10% FCS. On day 4 of the culture, the medium was changed and a 72-h incubation was performed in quadruplicate. ␣-Subunit (␣-SU), FSH, and LH concentrations in the media were determined as described in the Materials and Methods section. No detectable amounts of GH, PRL, and ACTH were found in the media. significantly inhibited insulin release by 29 and 32%, respectively (P Ͻ 0.01 vs. control). Octreotide (10 nm) and RC-160 (10 nm) were ineffective, however.
Insulinomas
Cells of insulinoma no. 2 were cultured in Transwells in the absence or presence of SS-14, SS-28, and SS-analogs. Figure 4 shows that SS-14, SS-28, and the SS-analogs octreotide, BIM-23014, and RC-160 progressively inhibited insulin release to the same extent. octreotide did not express the sst 2 subtype, however. In addition, no sst 2 mRNA expression was found in the other NFAs and prolactinomas. One pheochromocytoma and one carcinoid, which were already known to express sst 2 mRNA, were included as a positive controls for sst 2 mRNA expression (Table 5) . One NFA (no. 11), which showed binding of both radioligands, did not express sst 1 , sst 2 , or sst 3 mRNA. Two other adenomas (NFA no. 17 and prolactinoma no. 6) showed sst 3 expression, whereas no ligand binding was detected, possibly due to low levels of expression of the receptor protein. Furthermore, the expression of sst 1 and sst 3 was variable. Insulinoma no. 2, which had a high density of receptors, expressed sst 1 and sst 3 mRNA only (Fig. 5) .
Somatostatin receptor subtype expression
Discussion
Experimental and human tumors of different cellular origin express multiple sst subtypes. By various methods including RT-PCR, RNAse-protection, and in situ hybridization, it has been demonstrated that sst 1 , sst 2 , sst 3 , sst 4 , and sst 5 mRNA can be expressed in different human pituitary adenomas and insulinomas at the same time (7, 8, 19 -21) . The expression of multiple sst subtypes in tumors makes it difficult to establish their functional role in mediating antihormonal and/or antiproliferative effects. A subgroup of neuroendocrine tumors, including pituitary adenomas and insulinomas, express ssts with high affinity binding for SS-28 but not for octreotide (6) . In the present study, we have investigated the effects of native SS (SS-14 and/or SS-28) and of the three octapeptide SS-analogs octreotide, BIM-23014, and RC-160, on hormone release by cultured NFAs, prolacti- nomas, and insulinomas to further establish whether tumors lacking sst subtypes with high affinity for octapeptide SSanalogs (sst 2 and sst 5 ) can be responsive to native SS. This may give information whether sst subtypes other than sst 2 and sst 5 may be involved in the antihormonal actions of SS in such tumors.
We found that, in a small subgroup of NFA cultures (3/10), prolactinomas (3/4), and insulinomas (1/2), hormone release in vitro was insensitive or showed a very low sensitivity to the inhibitory effects of the octapeptide SS-analogs octreotide, RC-160 and BIM-23014, while at the same time hormone release was inhibited by SS-14 and/or SS-28. In line with the observation that the three octapeptide SS-analogs show a comparable binding profile to the five sst subtypes, we found no differences between the maximal inhibitory effects of octreotide, BIM-23014, and RC-160. Comparable results were found in GH-secreting adenomas in a previous study (10) . In this study, we also found that those adenoma cell cultures that did not respond to octreotide did not respond to BIM-23014 and RC-160 as well (10) . Octreotide, RC-160, and BIM-23014 bind with a high and relative high affinity to sst 2 and sst 5 , respectively, with low affinity to sst 3 , and display no binding to sst 1 and sst 4 (1) (2) (3) (4) . This suggests that the tumors mentioned above lack the expression of sst 2 , sst 5 , and possibly also sst 3 . In a few selected cases, sufficient tissue was obtained to perform both cell culture studies and ligand binding and in situ hybridization studies. In one NFA, which showed a high density of [ 125 I-Tyr 0 ]SS28 binding sites, and sst 1 mRNA expression only, hormone release was only slightly sensitive to SS-28 and not to octreotide, suggesting that activation of sst 1 is not important in mediating an antihormonal effect. However, ␤LH and ␤FSH secretion was not measured in our study. Previously, Klibansky et al. (12) showed that SS significantly inhibited ␤LH and ␤FSH secretion in vitro in 53% of patients with NFAs, whereas ␣-subunit secretion was inhibited in only 17% of these tumors. Further studies are needed to elucidate this point. Two prolactinomas that showed a low sensitivity to SS-28 in vitro expressed sst 1 and sst 3 mRNA, respectively. Prolactinoma no. 6, which responded to both octreotide and SS-28, did not express sst 2 , suggesting that sst subtypes other than sst 2 are involved in the regulation of hormone secretion in this particular case. On the other hand, the low density of SS binding sites may also account for their low sensitivity to SS in vitro. The insulinoma, which was highly sensitive to the inhibitory effects of SS-28, SS-14, as well as to the three octapeptide SS-analogs octreotide, BIM-23014 and RC-160, did not express sst 2 mRNA, suggesting that other sst subtypes (i.e. sst 5 ) are also important in mediating the inhibition of insulin release in this case. The involvement of sst 3 , which is also expressed in this case, cannot be fully excluded, however. Moreover, disregulation of receptor/signaling systems, like density of receptors, desensitization, signaling, or gene regulation, can be involved in determining the response of hormone secretion to SS and SS analogs as well.
In conclusion, sst subtypes other than sst 2 and sst 5 may mediate an antihormonal effect because, in particular tumors that were not responsive to the three octapeptide SS-analogs, native SS was effective. Therefore, it seems reasonable to develop sst 1 , sst 3 , and/or sst 4 -subtype selective SS-analogs for the treatment of this small subgroup of patients.
Our observations seem well in agreement with the results of studies by Greenman and Melmed (7, 19) . These investigators demonstrated by RNAse protection and RT-PCR assays the absence of sst 2 mRNA in prolactinomas, whereas the majority of the tumors expressed sst 1 (4 out of 5), sst 3 (3 out of 3), and sst 5 (3 out of 3) mRNA. It is also known for some time that the vast majority of the patients with prolactinomas do not respond to treatment with octreotide (22) (23) . However, data concerning sst subtype mRNA expression in pituitary adenomas are conflicting. Other groups demonstrated sst 2 mRNA expression by RT-PCR analysis in prolactinomas in 100, 67, and 100% of the cases, respectively (20, 21, 24) . The high sensitivity of the RT-PCR technique may be an explanation for this observation but also for the discrepancy between clinical studies using octreotide in prolactinoma patients on the one hand and the high incidence of sst 2 mRNA positive prolactinomas when evaluated by RT-PCR.
In conclusion, our study demonstrates that, in a subgroup of NFAs, prolactinomas, and insulinomas, hormone release is inhibited by native SS, but not by the octapeptide SSanalogs octreotide, RC-160, or BIM-23014. This suggests that, in selected neuroendocrine tumors, sst-subtypes other than sst 2 may be involved in the inhibition of hormone release and that novel sst-subtype specific SS-analogs might be of value in the treatment of selected patients harboring tumors with ssts with low affinity for octapeptide SS-analogs. 3 mRNA. B and C, Total binding was displaced with more than 50% by excess (1 M) unlabeled SS-28 or octreotide, respectively; D and F, the hybridization signal was displaced with more than 50% by a 20-fold excess unlabeled sst 1 or sst 3 oligonucleotide probe, respectively; E, the very low hybridization signal was not displaced by excess sst 2 oligonucleotide probe. Bar, 1 mm.
